StockData
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. (MTNB) stock

MTNBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$0.91+0.05 (+6.35%)

Close on Nov 18, 2026Market cap $13.37MP/E –Yield –

Matinas BioPharma cash

Cash and short-term investments held at the end of each period.

Matinas BioPharma's cash was $761.00K at Jun 30, 2026. For fiscal 2025 it was $4.00M, down 45.1% from the year before. Over ten years it grew 2.2% a year on average. The highest annual figure on record is $58.68M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$4.00M-45.1%
FY2024Dec 31, 2024$7.28M-47.0%
FY2023Dec 31, 2023$13.76M-52.2%
FY2022Dec 31, 2022$28.76M-42.0%
FY2021Dec 31, 2021$49.62M-15.4%
FY2020Dec 31, 2020$58.68M+111.3%
FY2019Dec 31, 2019$27.77M+113.5%
FY2018Dec 31, 2018$13.01M+78.0%
FY2017Dec 31, 2017$7.31M+78.0%
FY2016Dec 31, 2016$4.11M+27.2%
FY2015Dec 31, 2015$3.23M+24.6%
FY2014Dec 31, 2014$2.59M-76.1%
FY2013Dec 31, 2013$10.84M+2454.5%
FY2012Dec 31, 2012$424.36K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$761.00K-88.3%
Q1 FY2026Mar 31, 2026$2.40M-65.4%
Q4 FY2025Dec 31, 2025$4.00M-45.1%
Q3 FY2025Sep 30, 2025$5.44M-49.7%
Q2 FY2025Jun 30, 2025$6.53M-54.4%
Q1 FY2025Mar 31, 2025$6.92M-14.6%
Q4 FY2024Dec 31, 2024$7.28M-47.0%
Q3 FY2024Sep 30, 2024$10.80M-40.7%
Q2 FY2024Jun 30, 2024$14.31M-36.4%
Q1 FY2024Mar 31, 2024$8.11M-67.4%
Q4 FY2023Dec 31, 2023$13.76M-52.2%
Q3 FY2023Sep 30, 2023$18.22M-44.9%
Q2 FY2023Jun 30, 2023$22.51M-41.5%
Q1 FY2023Mar 31, 2023$24.86M-43.3%
Q4 FY2022Dec 31, 2022$28.76M-42.0%
Q3 FY2022Sep 30, 2022$33.05M-38.6%
Q2 FY2022Jun 30, 2022$38.50M-35.7%
Q1 FY2022Mar 31, 2022$43.87M-27.7%
Q4 FY2021Dec 31, 2021$49.62M-15.4%
Q3 FY2021Sep 30, 2021$53.83M-14.2%
Q2 FY2021Jun 30, 2021$59.84M-11.9%
Q1 FY2021Mar 31, 2021$60.67M-14.8%
Q4 FY2020Dec 31, 2020$58.68M+111.3%
Q3 FY2020Sep 30, 2020$62.77M+188678.3%
Q2 FY2020Jun 30, 2020$67.96M+181522.5%
Q1 FY2020Mar 31, 2020$71.17M+80.6%
Q4 FY2019Dec 31, 2019$27.77M+113.5%
Q3 FY2019Sep 30, 2019$33.25K-99.5%
Q2 FY2019Jun 30, 2019$37.42K-99.6%
Q1 FY2019Mar 31, 2019$39.41M+824.5%
Q4 FY2018Dec 31, 2018$13.01M+78.0%
Q3 FY2018Sep 30, 2018$6.63M-26.3%
Q2 FY2018Jun 30, 2018$8.90M-21.0%
Q1 FY2018Mar 31, 2018$4.26M-73.1%
Q4 FY2017Dec 31, 2017$7.31M+78.0%
Q3 FY2017Sep 30, 2017$9.00M+44.7%
Q2 FY2017Jun 30, 2017$11.27M–
Q1 FY2017Mar 31, 2017$15.83M–
Q4 FY2016Dec 31, 2016$4.11M–
Q3 FY2016Sep 30, 2016$6.22M–

More Matinas BioPharma figures

See a number that looks wrong?